16 September 2026 note archive · Item
Tandem Mobi Tubeless & Next-Gen Patch (Control-IQ+ / Sigi): review notes
These archived notes document the scope reviewed on 16 September, including source-access limits. They do not cover later changes or newly added records. They are not independent clinical certification or a guarantee that every claim was verified.
Read the item evidence page →Thriving evidence review — 16 September 2026
Record: Next-generation Mobi patch pump (Sigi technology)
Scope and findings:
- Registry protocol/status/outcome scope checked; NCT05973422: UNKNOWN, primary completion {'date': '2024-09-30', 'type': 'ESTIMATED'}, {'count': 10, 'type': 'ESTIMATED'}. No new results inferred from completion dates; product approval/access and older clinical scores are separate checks.
- Read manufacturer pipeline updated August6: Sigi-derived next-generation Mobi is distinct from current Mobi tubeless infusion-site submission; no next-generation launch date.
Primary sources checked:
Limits: The review is restricted to the scopes above. Historical efficacy estimates, editorial scoring and country-specific access were not fully reverified unless expressly stated. A manufacturer or conference report retains that evidence level.